<DOC>
	<DOCNO>NCT02033876</DOCNO>
	<brief_summary>This study evaluate whether bile acid able increase insulin sensitivity enhance glycemic control T2DM patient , well explore mechanism enhance glycemic control . These observation provide preliminary data propose future therapeutic well mechanistic study role bile acid control glycemia T2DM .</brief_summary>
	<brief_title>Ursodiol Insulin Sensitivity , Gastric Emptying Body Weight With Type 2 Diabetes Metformin</brief_title>
	<detailed_description>Background : Intra-jejunal administration bile acid improves insulin sensitivity . Hypothesis : The bile acid , ursodeoxycholic acid ( UDCA ) delay ( ileocolonic ) -release formulation , stimulate TGR-5 FXR receptor ileum colon , increase secretion FGF-19 , GLP-1 , oxyntomodulin ( OXM ) , PYY3-36 , improve insulin sensitivity induce weight loss . Aim : To study effect ileocolonic formulation UDCA insulin sensitivity , postprandial plasma glycemia incretin level , gastric empty body weight overweight obese type 2 diabetic subject monotherapy metformin . Study design : This single center , placebo-controlled , parallel group , single dose randomize control trial study effect delay ( ileocolonic ) -release UDCA 600 mg twice daily insulin sensitivity , gastric empty liquid solid ( measure scintigraphy ) weight loss overweight obese type 2 diabetic subject . Participants receive monotherapy metformin . Blood sample collect defined time measure glycemia incretin ( GLP-1 , OXM , PYY3-36 ) fasting level responses meal . Anticipated Results : In comparison placebo , UDCA increase insulin sensitivity , enhance glycemic control , increase postprandial incretins , delay GE liquid . Significance : This study prove ileocolonic-release UDCA enhances glycemic control T2DM patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Overweight Obese subject BMI &gt; 25 Kg/m2 Type 2 Diabetes mellitus Metformin , receive standard care Type 2 DM . Otherwise individual currently treatment cardiac , pulmonary , gastrointestinal , hepatic , renal , hematological , neurological , endocrine ( T2DM ) unstable psychiatric disease . Men woman . Women childbearing potential negative pregnancy test initiation medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>